How Tirzepatide Works: Two Hormones, Not One

Tirzepatide gets described as a GLP-1 medication, which is close enough to be useful and wrong enough to be worth correcting. It acts on two receptors, not one, and understanding the second one explains most of what makes it a different drug.

Start with what these hormones do

GLP-1 and GIP are both incretins, hormones your gut releases when you eat. They are part of the signaling loop that tells your body food has arrived.

GLP-1 does several things at once. It prompts the pancreas to release insulin in a glucose dependent way, meaning it responds to how much sugar is actually present rather than firing regardless. It slows how quickly the stomach empties. And it acts on appetite regulation in the brain, which is the part most people notice.

GIP is the other major incretin, and its role in body weight has been argued about for years. It also stimulates glucose dependent insulin release. Its effects on fat tissue and on appetite signaling are the subject of a genuinely active scientific debate, one that has not fully settled.

What tirzepatide does with both

Tirzepatide is a single molecule that binds both receptors. That is the structural difference from a medication that targets GLP-1 alone.

It does not hit them evenly, and that is by design rather than accident. Pharmacology work published in 2020 characterized tirzepatide as an imbalanced and biased dual agonist. In plain terms, two things are true about how it behaves.

First, it is imbalanced: it acts more strongly at the GIP receptor than at the GLP-1 receptor, relative to how the natural hormones behave at each.

Second, it is biased at the GLP-1 receptor. When a receptor is activated it can trigger more than one downstream pathway. Tirzepatide favors cAMP signaling over beta-arrestin recruitment. Beta-arrestin is involved in pulling receptors off the cell surface after activation, so favoring the other pathway changes how the receptor behaves over repeated dosing.

The short version: it mimics natural GIP closely at the GIP receptor, and engages the GLP-1 receptor in a deliberately lopsided way.

Why anyone bothered adding GIP

For a long time the assumption ran the other way. Blocking GIP, rather than activating it, was considered the more plausible route for treating obesity, and there are still researchers making that case.

The counterargument, laid out in a 2025 review in the American Diabetes Association's journal Diabetes, is that sustained GIP receptor agonism produces effects on energy balance that differ from what short term physiology would predict. This is an area where the mechanism is still being worked out, and honest sources say so.

What is not in dispute is that trials of the dual agonist reported substantial average weight reductions. Exactly how much of that traces to the GIP component remains an open question.

What this does and does not tell you

Mechanism is useful for understanding a medication. It is not a substitute for evidence about outcomes, and it is definitely not a substitute for knowing whether something suits you.

A cleaner mechanism does not mean better tolerated. Acting on two receptors means two sets of effects, including the gastrointestinal ones that lead some people to stop. The molecular story explains what the drug is doing. It does not predict what it will do in you.

If you want the outcome data rather than the mechanism, we wrote separately about what the three year trial found.